Octamethylcyclotetrasiloxane


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:11509742IVR250 mg/kg/day 250 mg/kg/dayAffects uterine morphologyReproductive endocrine-mediated perturbations
IVR10 mg/kg/day -No significant effects observed-
IVR50 mg/kg/day -No significant effects observed-
IVR100 mg/kg/day -No significant effects observed-
IVR250 mg/kg/day 250 mg/kg/dayIncreased uterine weightsReproductive endocrine-mediated perturbations
IVR1000 mg/kg/day 1000 mg/kg/dayIncreased uterine weightsReproductive endocrine-mediated perturbations
IVR1000 mg/kg/day 1000 mg/kg/dayAffects uterine morphologyReproductive endocrine-mediated perturbations
IVR500 mg/kg/day 500 mg/kg/dayAffects uterine morphologyReproductive endocrine-mediated perturbations
IVR500 mg/kg/day 500 mg/kg/dayIncreased uterine weightsReproductive endocrine-mediated perturbations
PMID:17418525IVR7 - 9 ppm 7 - 9 ppmAffects ovulationReproductive endocrine-mediated perturbations
IVR7 - 9 ppm 7 - 9 ppmIncreased estrone levelsReproductive endocrine-mediated perturbations
IVR7 - 9 ppm 7 - 9 ppmAffects ovarian follicles populationReproductive endocrine-mediated perturbations
IVR7 - 9 ppm 7 - 9 ppmDecreased E1/E2 ratioReproductive endocrine-mediated perturbations
IVR7 - 9 ppm 7 - 9 ppmDecreased FSH levelsReproductive endocrine-mediated perturbations
IVR7 - 9 ppm 7 - 9 ppmIncreased estradiol levelsReproductive endocrine-mediated perturbations
IVR9 ppm 9 ppmDecreased uterine weightsReproductive endocrine-mediated perturbations
IVR7 - 9 ppm 7 - 9 ppmDecreased prolactin levelsReproductive endocrine-mediated perturbations
IVR7 - 9 ppm 7 - 9 ppmDecreased LH levelsReproductive endocrine-mediated perturbations
IVR9 ppm 9 ppmDecreased ovarian weightsReproductive endocrine-mediated perturbations
IVR9 ppm 9 ppmIncreased progesterone levelsReproductive endocrine-mediated perturbations
IVR7 - 9 ppm 7 - 9 ppmDecreased body weightsMetabolic endocrine-mediated perturbations
PMID:34884750IVR5 mg/kg 5 mg/kgAffects survival of live fetusReproductive endocrine-mediated perturbations
IVR5 mg/kg 5 mg/kgDecreased brain weightsNeurological endocrine-mediated perturbations
IVR5 - 25 mg/kg 5 - 25 mg/kgCognitive impairmentNeurological endocrine-mediated perturbations
IVR5 - 25 mg/kg 5 - 25 mg/kgInduce behavioral changesNeurological endocrine-mediated perturbations
IVR5 - 25 mg/kg 5 - 25 mg/kgAltered cell cycle in neuronsNeurological endocrine-mediated perturbations
IVR1 - 25 mg/kg 1 - 25 mg/kgAffects expression of estrogen receptor-alpha (ER-alpha)Reproductive endocrine-mediated perturbations
IVR5 - 25 mg/kg 5 - 25 mg/kgAffects expression of estrogen receptor-beta (ER-beta)Reproductive endocrine-mediated perturbations
IVR1 - 25 mg/kg 1 - 25 mg/kgIncreased uterine weightsReproductive endocrine-mediated perturbations
IVR5 - 25 mg/kg 5 - 25 mg/kgAffects spatial learningNeurological endocrine-mediated perturbations
IVR1 - 25 mg/kg 1 - 25 mg/kgAffects neural developmentDevelopmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.